N-(Azaaryl)Cyclolactam-1-Carboxamide Derivative, Preparation Method Therefor, And Use Thereof
Patent No. EP3632907 (titled "N-(Azaaryl)Cyclolactam-1-Carboxamide Derivative, Preparation Method Therefor, And Use Thereof") was filed by Abbisko Therapeutics on May 22, 2018. The application was issued on Feb 28, 2024.
Patent Summary
N-(azaaryl)cyclolactam-1-carboxamide derivatives with enhanced selectivity and therapeutic window for cancer treatment, particularly in ovarian, pancreatic, and lung cancers. The compounds exhibit potent inhibition of CSF-1R kinase activity while maintaining selectivity against other kinases, thereby reducing immunogenic side effects. The compounds can be prepared through a novel synthesis pathway involving a specific intermediate.
Patent Family
Patent Oppositions
Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.
Dossier Documents
The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.
Date
Description
Get instant alerts for new documents
EP3632907
- Application Number
- EP18805288A
- Filing Date
- May 22, 2018
- Status
- Granted And Under Opposition
- Jan 26, 2024
- Publication Date
- Feb 28, 2024
- External Links
- Slate, Register , Google Patents